Canine pancreatitis injectable lands U.S. distributionMay 18, 2023Panoquell-CA1’s active ingredient, fuzapladib sodium, has been approved for canine use in Japan since 2018.
Education Center - SponsoredHow AI-Enabled Diagnostic Platforms are Buying Back Time for Veterinarians and Cliniciansby • Zoetis DiagnosticsIn the right context, AI yields the power to enhance clinical confidence and streamline decision-making – without replacing the human touch that defines the profession.
Canine pancreatitis injectable OKed by FDANovember 21, 2022Panoquell-CA1 has been granted conditional approval from the U.S. Food and Drug Administration (FDA) for the management of clinical signs associated with acute onset of pancreatitis in canines.
Clinical trial aims to treat canine pancreatitisFebruary 6, 2020ISK and AlcheraBio are seeking clinics to serve as clinical investigator sites to explore treatment options for patients diagnosed with acute canine pancreatitis (ACP).
